Literature DB >> 2437109

Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelope.

R C Kennedy, G R Dreesman, T C Chanh, R N Boswell, J S Allan, T H Lee, M Essex, J T Sparrow, D D Ho, P Kanda.   

Abstract

A polyamide-based solid-phase support containing an acid-stable p-(oxymethyl)benzoic acid handle to anchor the COOH-terminal amino acid was utilized in the production of synthetic peptides analogous to amino acid sequences 503-532 from the human immunodeficiency virus (HIV) envelope glycoprotein. The resin-bound peptide was used to induce an antibody response to the native form of glycoprotein 120 in both rabbits and mice. This epitope was detected on the surface of HIV-infected cells and was capable of inducing an in vitro neutralizing HIV antibody response. In addition, sera from some individuals exposed to HIV react with this peptide bound to the resin in a solid-phase immunoassay. These data indicate that we have identified a neutralizing antigenic determinant present on the amino-terminal glycoprotein 120 subunits of HIV by utilizing resin-bound synthetic peptides.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2437109

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.

Authors:  R Q Warren; S A Anderson; W M Nkya; J F Shao; C W Hendrix; G P Melcher; R R Redfield; R C Kennedy
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

2.  Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env.

Authors:  L Gritz; A Destree; N Cormier; E Day; V Stallard; T Caiazzo; G Mazzara; D Panicali
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

3.  A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization.

Authors:  P A Broliden; K Ljunggren; J Hinkula; E Norrby; L Akerblom; B Wahren
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

4.  Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees.

Authors:  R Q Warren; H Wolf; K R Shuler; J W Eichberg; R A Zajac; R N Boswell; P Kanda; R C Kennedy
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

5.  Patterns of antibody reactivity to selected human immunodeficiency virus type 1 (HIV-1) gp160 epitopes infected individuals grouped according to CD4+ cell levels.

Authors:  R Q Warren; H Wolf; R A Zajac; R N Boswell; P Kanda; R C Kennedy
Journal:  J Clin Immunol       Date:  1991-01       Impact factor: 8.317

6.  Human MoAbs produced from normal, HIV-1-negative donors and specific for glycoprotein gp120 of the HIV-1 envelope.

Authors:  M Ohlin; J Hinkula; P A Broliden; R Grunow; C A Borrebaeck; B Wahren
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

7.  Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Authors:  T J Palker; M E Clark; A J Langlois; T J Matthews; K J Weinhold; R R Randall; D P Bolognesi; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

8.  Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.

Authors:  J P Moore; D D Ho
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

Review 9.  Viral and Host Factors Regulating HIV-1 Envelope Protein Trafficking and Particle Incorporation.

Authors:  Boris Anokhin; Paul Spearman
Journal:  Viruses       Date:  2022-08-05       Impact factor: 5.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.